<DOC>
	<DOCNO>NCT02307461</DOCNO>
	<brief_summary>To Evaluate Bioequivalence two formulation IPI-145 Effect Food Pharmacokinetics IPI-145</brief_summary>
	<brief_title>Bioequivalence Duvelisib Food Effect Pharmacokinetics IPI-145</brief_title>
	<detailed_description>This Phase 1 , randomize , open-label study IPI-145 conduct 2 part . Part 1 conduct 2 cohort . Cohort 1 consist 32 healthy subject , Cohort 2 consist 52 healthy subject . Subjects cohort receive 2 dos IPI fast condition 2-period , 2-sequence crossover design . Dosing Period 1 Period 2 separate least 7 day . Part 2 2-period , 2-sequence crossover design assess effect high-fat meal PK IPI-145 20 subject . Subjects receive single oral dos feed ( high-fat meal ) fast condition , separate least 7 day .</detailed_description>
	<criteria>Men woman nonchild bear potential 1850 year age Body Mass Index ( BMI ) : 18.0 32.0 kg/m2 . Healthy subject : good health , determine clinically significant finding clinical evaluation Provided write informed consent prior study specific procedure Women childbearing potential Healthy subject : positive screen test hepatitis B surface antigen , hepatitis C antibody , HIV1/HIV2 antibodies ECG screen show QTcF â‰¥ 450 msec Evidence clinically significant medical condition History gastrointestinal disease surgery may affect drug absorption Positive TSpot ( tuberculosis ) TB test screen Any active infection time screen admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Food</keyword>
	<keyword>Healthy Adult</keyword>
</DOC>